RADX

Radiopharm Theranostics Ltd ADR

2.08

Sep 04 • 3:59 PM ET -0.08 (-3.48%)

2.08

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology Australia Nano NASD

Peers: RNTX TELO AVXL GLSI INDP PALI PRLD TARA ARTV RZLT

Scroll to Statements

Index	-
Market Cap	30.08M
Enterprise Value	25.57M
Income	-37.47M
Sales	1.88M
Book/sh	1.45
Cash/sh	0.20
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	14
IPO	Dec 05, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	16.00
P/B	1.44
P/C	10.48
P/FCF	-
EV/EBITDA	-
EV/Sales	13.60
Quick Ratio	3.01
Current Ratio	1.16
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-3.17
EPS next Y	-4.06
EPS next Q	-
EPS this Y	25.26%
EPS next Y	-40.56%
EPS next 5Y	-
EPS past 3/5Y	47.27% -51.82%
Sales past 3/5Y	112.06% -
EPS Y/Y TTM	8.58%
Sales Y/Y TTM	-19.76%
EPS Q/Q	-15.85%
Sales Q/Q	-31.95%
Earnings	Aug 28 AMC
EPS/Sales Surpr.	0.00% 0.00%

Insider Own	-
Insider Trans	-
Inst Own	1.97%
Inst Trans	-96.69%
ROA	-76.21%
ROE	-161.31%
ROIC	-108.51%
Gross Margin	9.59%
Oper. Margin	-2556.26%
Profit Margin	-1994.08%
SMA20	-15.15%
SMA50	-36.85%
SMA200	-52.59%
Trades

Shs Outstand	11.81M
Shs Float	-
Short Float	-
Short Ratio	0.37
Short Interest	0.03M
52W High	16.25 -87.20%
52W Low	2.04 1.78%
Volatility	8.30% 8.94%
ATR (14)	0.25
RSI (14)	26.06
Beta	1.07
Rel Volume	0.11
Avg Volume	73.84K
Volume	7,909

Perf Week	-13.69%
Perf Month	-25.45%
Perf Quarter	-51.85%
Perf Half Y	-58.32%
Perf YTD	-60.15%
Perf Year	-62.86%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	14.38
Prev Close	2.15
Price	2.08
Change %	-3.48%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-04-26	Initiated	H.C. Wainwright	Buy	$6
Mar-12-25	Initiated	B. Riley Securities	Buy	$15

Aug-26-26 07:00AM	Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors (GlobeNewswire) -6.45%
Aug-20-26 07:00AM	Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial (GlobeNewswire) -8.40%
Aug-17-26 07:30AM	Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases (GlobeNewswire)
Jul-31-26 07:00AM	Radiopharm Theranostics Reports Business Update (GlobeNewswire)
Jul-24-26 07:15AM	Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan (GlobeNewswire) -17.25%
07:05AM	Loading…
Jul-22-26 07:05AM	Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy (GlobeNewswire)
07:00AM	Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases (GlobeNewswire)
Apr-23-26 07:00AM	Radiopharm Theranostics Reports Business Update (GlobeNewswire)
Apr-20-26 07:00AM	Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026 (GlobeNewswire)
Apr-16-26 07:00AM	Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases (GlobeNewswire)
Apr-08-26 07:00AM	Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial (GlobeNewswire)
Apr-07-26 07:00AM	Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S. (GlobeNewswire)
Mar-27-26 07:00AM	Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer (GlobeNewswire)
Mar-26-26 07:20PM	Radiopharm advances RAD 402 into clinic with first patient dosed in Phase 1 trial (Proactive)
07:20PM	Inside Biotech: Radiopharm advances RAD 402 into clinic with first patient dosed in Phase 1 trial (Proactive)
07:00AM	Loading…
Mar-24-26 07:00AM	Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases (GlobeNewswire) -10.78%
Feb-24-26 07:30AM	Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01) (GlobeNewswire)
Jan-28-26 07:00AM	Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates (GlobeNewswire)
Jan-12-26 07:00AM	RAD Increases Ownership in Radiopharm Ventures to 87.5% (GlobeNewswire)
Dec-15-25 12:35PM	Radiopharm (RADX) Sees Slight Pessimism From Analysts (Insider Monkey) +149.53%
07:00AM	Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases (GlobeNewswire)
Nov-18-25 08:30AM	Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer (GlobeNewswire)
Nov-17-25 08:00AM	Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging in Brain Metastases (GlobeNewswire)
Nov-12-25 08:30AM	Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204 (GlobeNewswire)
Oct-20-25 08:00AM	Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs (GlobeNewswire) -19.83%
07:30AM	Radiopharm Theranostics completes A$35 million Placement and launches a A$5 million Share Purchase Plan (GlobeNewswire)
Oct-02-25 08:15AM	Radiopharm receives DSMC recommendation to advance Phase 1 HEAT trial (TipRanks) +5.57%
Oct-01-25 08:00AM	Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to Accelerate 177Lu-RAD202 Phase 1 'HEAT' Dose Escalation Clinical Trial (GlobeNewswire)
Aug-17-25 01:52AM	Radiopharm Theranostics Limited (RADX) Receives IND Approval From FDA To Initiate Phase I Therapeutic Clinical Study To Target B7H3 With Betabart (RV-01) (Insider Monkey)
Jul-29-25 07:30AM	Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update (GlobeNewswire)
08:00AM	Loading…
Jul-28-25 08:00AM	Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01) (GlobeNewswire)
Jul-22-25 08:00AM	Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board (GlobeNewswire)
Jun-24-25 08:00AM	Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹6¹Tb-KLK3-mAb Phase I Clinical Trial in Australia (GlobeNewswire) +5.69%
Jun-11-25 08:00AM	Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases (GlobeNewswire) -5.84%
Jun-04-25 08:00AM	Radiopharm Theranostics Doses First Patient in Phase 1 'HEAT' Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors (GlobeNewswire)
Jun-02-25 08:00AM	Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake (GlobeNewswire) +11.16%
May-19-25 08:00AM	ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177 (GlobeNewswire)
May-12-25 08:00AM	Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee (DSMC) (GlobeNewswire)
May-07-25 08:00AM	Radiopharm Theranostics to Participate in the D. Boral Capital Inaugural Global Conference (GlobeNewswire)
Apr-28-25 08:00AM	Radiopharm Theranostics Doses First Patient with 18F-RAD101 in U.S. Phase 2b Imaging Study of Brain Metastasis (GlobeNewswire)
Mar-27-25 03:13PM	Radiopharm Theranostics: Radiotherapeutic Biotech With PD-L1 And HER2 Targeting (SeekingAlpha)
Mar-17-25 08:56AM	New RAD202 Data Confirms Positive Tumor Uptake and Favorable Biodistribution (GlobeNewswire) +6.90%
Feb-10-25 08:00AM	New Clinical Trial Data Highlights RAD 101 (18F-Pivalate) Successfully Detects Brain Metastases (GlobeNewswire)
Jan-10-25 08:00AM	Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement (GlobeNewswire) +32.75%
Dec-30-24 08:00AM	Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia (GlobeNewswire)
Dec-20-24 08:00AM	RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial (GlobeNewswire)
Nov-27-24 08:00AM	Radiopharm Achieves Nasdaq Listing of American Depositary Shares (GlobeNewswire)

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is founded by Paul A. Hopper in 2021 headquartered Carlton, Australia.

B.A (UNSW)Mr. Paul Edward-Alexander Hopper A.S.i.A

MDMr. Riccardo Canevari

Chief Medical OfficerDr. Dimitris Voliotis M.D.

Chief Financial OfficerMr. Aaron Laurita

Head of Project ManagementMr. Hitesh Goel

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RADX

Radiopharm Theranostics Ltd ADR

Upgrade your Finviz experience